NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Danish biotech and healthcare sector rose 4.8%. Most notably, Scandion Oncology got delisted and is closing the company, Acarix announced its first order in the MENA region, ExpreS2ion got access to DTU’s supercomputer, Zeland Pharma got new price targets, and the subscription period of Pila Pharma’s rights issue ends tomorrow.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
Acarix announced its first order in the Middle East and North Africa region valued at MSEK 1.35.
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
Ascendis Pharma is presenting data from its phase 3 PaTHway Trial at ENDO 2025 from July 12-15 in San Francisco.
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
No news in the past week
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.
No news in the past week
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
No news in the past week
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
DanCann Pharma announced that they have received a conditional sales agreement regarding the sale of its production facility, Biotech Pharm1 (“BP1”), at a total consideration of EUR 1.25 million (DKK 9.32 million). In continuation of this, the Company has secured bridge financing for DKK 2 million to bridge liquidity until the final sale of BP1, and to help propel its new Maturity2028 strategy.
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion warrants
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
No news in the past week
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
No news in the past week
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.
No news in the past week
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
No news in the past week
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
No news in the past week
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
Pila Pharma’s MSEK 20 has its last subscription day tomorrow on July 15, and 99.87% of the rights issue is already guranteed.
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
No news in the past week
Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges, thus, financial stability is the main driver for the stock price.
Scandion Oncology has closed its activities and got delisted last week.
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
No news in the past week
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news in the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
No news in the past week
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in its late-stage pipeline and partnerships are key stock price influencers.
Barclays initiated coverage on Zealand Pharma at DKK 560, while Deutsche Bank lowered their price target from DKK 485 to DKK 400.
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
No news in the past week
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks delivered a return of 4.8%. Most notably, Acarix announced its first order in the MENA region at MSEK 1.35, and DanCann Pharma reached a conditional sales agreement for its production facility at a total consideration of EUR 1.25. Furthermore, Evaxion Biotech made a debt settlement agreement with the European Investment Bank for MEUR 3.5 out of its MEUR 7 loan, and ExpreS2ion got access to DTU’s supercomputer. Finally, the subscription period of Pila Pharma’s rights issue ends tomorrow at July 15, Scandion Oncology got delisted, and Zealand Pharma got new price targets significantly higher than their current stock price.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
